Tazicef Side Effects Center

Last updated on RxList: 11/22/2021
Tazicef Side Effects Center

What Is Tazicef?

Tazicef (ceftazidime) is a broad-spectrum antibiotic indicated for the treatment of patients with infections (lower respiratory tract infections, skin infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, and central nervous system infections) caused by susceptible strains of the designated organisms.

What Are Side Effects of Tazicef?

Common side effects of Tazicef include:

Dosage for Tazicef

The usual adult dosage of Tazicef is 1 gram administered intravenously or intramuscularly every 8 to 12 hours.

What Drugs, Substances, or Supplements Interact with Tazicef?

Tazicef may interact with aminoglycoside antibiotics, diuretics, chloramphenicol, and oral estrogen/progesterone contraceptives. Tell your doctor all medications and supplements you use.

Tazicef During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or become pregnant while taking Tazicef. It is unknown if it would affect a fetus. Tazicef passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Tazicef (ceftazidime) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Fungal Skin Infections: Types, Symptoms, and Treatments See Slideshow
Tazicef Consumer Information

3 pharmacies near 20147 have coupons for tazicef (Brand Names:Tazicef for 1-5GM-%(50ML))

Harris Teeter Pharmacy
Harris Teeter Pharmacy
$147.07

with free coupon

View Coupon
CVS Pharmacy
CVS Pharmacy
$149.89

with free coupon

View Coupon
Walgreens
Walgreens
$150.82

with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction (hives, itching, feeling light-headed, wheezing, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Call your doctor at once if you have:

  • severe stomach pain, diarrhea that is watery or bloody (even if it occurs months after your last dose);
  • pale or yellowed skin, dark colored urine, fever, or weakness;
  • confusion, hallucinations, severe weakness;
  • involuntary muscle movement;
  • seizure (black-out or convulsions); or
  • a cold feeling, discoloration, or skin changes in your fingers.

Common side effects may include:

  • allergic reaction;
  • numbness, tingling, burning pain;
  • headache, dizziness;
  • nausea, vomiting, diarrhea, stomach pain; or
  • signs of a fungal infection--sores or white patches in your mouth or throat, vaginal itching or discharge.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Tazicef (Ceftazidime Injection)

QUESTION

Bowel regularity means a bowel movement every day. See Answer
Tazicef Professional Information

SIDE EFFECTS

Ceftazidime is generally well tolerated. The incidence of adverse reactions associated with the administration of ceftazidime was low in clinical trials. The most common were local reactions following IV injection and allergic and gastrointestinal reactions. Other adverse reactions were encountered infrequently. No disulfiram-like reactions were reported.

The following adverse effects from clinical trials were considered to be either related to ceftazidime therapy or were of uncertain etiology:

Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients).

Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever. Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been reported with cephalosporin antibacterial drugs, including ceftazidime. Angioedema and anaphylaxis (bronchospasm and/or hypotension) have been reported very rarely.

Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78), nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS).

Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime (see PRECAUTIONS: General).

Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and vaginitis.

Hematologic

Rare cases of hemolytic anemia have been reported.

Laboratory Test Changes noted during clinical trials with Tazicef (ceftazidime for injection, USP) were transient and included: eosinophilia (1 in 13), positive Coombs test without hemolysis (1 in 23), thrombocytosis (1 in 45), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase (AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19), and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and lymphocytosis were seen very rarely.

Postmarketing Experience With Tazicef (Ceftazidime For Injection, USP) Products

In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with Tazicef and were reported spontaneously. For some of these events, data are insufficient to allow an estimate of incidence or to establish causation.

General

Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria; pain at injection site.

Hepatobiliary Tract

Hyperbilirubinemia, jaundice.

Renal And Genitourinary

Renal impairment

Cephalosporin-Class Adverse Reactions

In addition to the adverse reactions listed above that have been observed in patients treated with ceftazidime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs:

Adverse Reactions

Colitis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage.

Altered Laboratory Tests

Prolonged prothrombin time, false-positive test for urinary glucose, pancytopenia.

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs. Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials.

Chloramphenicol has been shown to be antagonistic to beta-lactam antibacterial drugs, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.

Read the entire FDA prescribing information for Tazicef (Ceftazidime Injection)

© Tazicef Patient Information is supplied by Cerner Multum, Inc. and Tazicef Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors